Transaction · 0001228684-26-000010
TARSTarsus Pharmaceuticals, Inc.
Link William J Phd
LINK WILLIAM J PHD, DIR, reported a transaction classified as exercise at Tarsus Pharmaceuticals, Inc. involving 201.000000 shares for an estimated $0.00. Reported holdings after the transaction were 605.000000 shares. The stored filing text includes a detected 10b5-1 reference.
exerciseSEC transaction code MDIR
- Trade date
- Sep 15, 2026
- Filing date
- Sep 17, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
TARS price since this filing
Daily closing prices, with the filing date and available return windowsTARS · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -12.4%1w ago -8.9%1d ago +1.2%
Returns since7d -3.9%30d -13.9%90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001228684-26-000010 Restricted Stock Units
- Transaction date
- Sep 15, 2026 Filed Sep 17, 2026, 08:22 PM · 2d delay
- Shares
- 201 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 605 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction 10b5-1 Detected
Filing-only score
-16 points
Compact filing score computed from stored Form 4 facts. Version v1.
Mixed or weak signal
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
No officer title
Officer NoDirector Yes10% NoOther No
Footnotes & amended
- F1
The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- F2
The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.
- F3
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide…
- F4
The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide…
- F5
Each RSU represents a contingent right to receive one share of the Company's common stock.
- F6
RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/…
Related transactions
Same SEC filing0 other transactions
Recent company activity
TARS0 recent txs